BioSpace News Archive

Portage Biotech Inc. (“Portage” or the “Company”) wishes to provide an update on a subsidiary company, Saugatuck Therapeutics Ltd. (“Saugatuck”). Portage Biotech Inc. holds an 70% equity interest in Saugatuck. Portage is pleased to announce that initial proof of concept of the n

CDISC has launched a project that will facilitate the use of electronic health record data in clinical research to achieve efficiencies that expedite global regulatory reviews, contribute to the evaluation of new treatments for patients and drive next generation discovery.

Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense, announced that they have successfully closed their most recent funding round totaling $5 million.

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2020. “Despite the challenges and disruptions inflicted by COVID-19, Stereotaxis continues to support the patients and physicians that rely on its technology, maintain effective operations, rapidly advance strategic innovations, and protect its financial s

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that it has initiated testing of its CB5064 analogs in preclinical models of ARDS, to assess their potential as therapeutics for coronavirus disease 2019 (COVID-19) associated ARDS. In preclinical studies to date, these peptides have demonstrated the ability to a

Swift Biosciences, Inc., a leader in commercialization of DNA and RNA library preparation kits for Next-Generation Sequencing (NGS), announced the release of its Swift Amplicon SARS-CoV-2 Research Panel. Targeting the full viral genome in a single reaction with a rapid 2-hour workflow, Swift’s assay meets research and surveillance need

DarioHealth Corp. (Nasdaq: DRIO) (“DarioHealth” or the “Company”), a pioneer in the global digital therapeutics market, announced it will release its first quarter ended March 31, 2020 financial results on Tuesday, May 12, 2020 , and host

Tennessee’s Medicaid program, TennCare, will cover Proteus Discover® to aid patients and physicians in the treatment of Hepatitis C.

New Return-to-Work Offerings Help Employers Reduce Risk While Welcoming Employees Back, Bringing Confidence to Worksites